Intra-Cellular Therapies Inc (ITCI)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

430 EAST 29TH STREET NEW YORK, NY 10016

Intra-Cellular Therapies Inc. researches and develops biopharmaceutical drugs. The company engages in the research and development of small molecule drugs to treat neuropsychiatric and neurological diseases and other disorders of the central nervous system. Intra-Cellular Therapies offers its products to the medical industry.

Data based on most recent fiscal year report
Market Cap1.405 Billion Shares Outstanding55.26 Million Avg Volume1.593 Million
1-Yr BETA vs S&P TR0.916 Current Ratio9.79 Quick Ratio9.79
View SEC Filings from ITCI instead.

View recent insider trading info

Funds Holding ITCI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ITCI BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

VAN NOSTRAND ROBERT L

  • Director
7,292 2020-03-31 5

RIGGS RORY B

  • Director
272,421 2020-03-31 5

ALAFI CHRISTOPHER D

  • Director
5,691,633 2020-03-31 10

LERNER RICHARD A

  • Director
83,743 2020-03-31 5

MARCUS JOEL S EXECUTIVE CHAIRMAN

  • Officer
  • Director
436,931 2020-03-31 2

HINELINE LAWRENCE J. SVP OF FINANCE CFO

  • Officer
0 2020-02-18 6

MATES SHARON CHAIRMAN, PRESIDENT & CEO

  • Officer
  • Director
0 2020-02-18 5

HALSTEAD MICHAEL EVP AND GENERAL COUNSEL

  • Officer
0 2020-02-18 5

SATLIN ANDREW EVP AND CHIEF MEDICAL OFFICER

  • Officer
0 2020-02-18 2

NEUMANN MARK EVP, CHIEF COMMERCIAL OFFICER

  • Officer
0 2020-02-18 3

VANOVER KIMBERLY E. SVP, EARLY STAGE CLINICAL DEV.

  • Officer
27,068 2019-01-04 0

DAVIS ROBERT E SVP, CHIEF SCIENTIFIC OFFICER

  • Officer
43,989 2019-01-04 0

ALAFI MOSHE

  • 10% Owner
3,953,270 2017-10-02 0

ALAFI CAPITAL CO LLC

  • 10% Owner
3,953,270 2017-10-02 0

FIENBERG ALLEN A. VP OF BUSINESS DEVELOPMENT

  • Officer
492,823 2015-08-19 0

WENNOGLE LAWRENCE P. VICE PRESIDENT, DRUG DISCOVERY

  • Officer
126,500 2015-06-08 0

SOSLAND MORTON I.

  • 10% Owner
3,638,389 2015-03-11 0

SANCHEZ JUAN F. VP, CORP. COMMUNICATIONS & IR

  • Officer
0 2015-01-02 0

RAWLINS MICHAEL

  • Director
0 2014-06-30 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

RIGGS RORY B - Director

2020-03-31 A 1,024 $15.37 a 45,751 272,421.00 direct

LERNER RICHARD A - Director held by the lerner family trust uad 11/14/94

2020-03-31 A 975 $15.37 a 72,313 83,743.00 indirect

VAN NOSTRAND ROBERT L - Director

2020-03-31 A 460 $15.37 a 7,292 7,292.00 direct

ALAFI CHRISTOPHER D - Director

2020-03-31 A 1,024 $15.37 a 344,610 5,691,633.00 direct

MATES SHARON - Director - Officer CHAIRMAN, PRESIDENT & CEO

2020-02-18 A 66,886 a 66,886 0.00 direct

SATLIN ANDREW - Officer EVP AND CHIEF MEDICAL OFFICER

2020-02-18 A 26,754 a 26,754 0.00 direct

HINELINE LAWRENCE J. - Officer SVP OF FINANCE CFO

2020-02-18 A 31,328 a 31,328 0.00 direct

HALSTEAD MICHAEL - Officer EVP AND GENERAL COUNSEL

2020-02-18 A 26,754 a 26,754 0.00 direct

NEUMANN MARK - Officer EVP, CHIEF COMMERCIAL OFFICER

2020-02-18 A 33,417 a 33,417 0.00 direct

HINELINE LAWRENCE J. - Officer SVP OF FINANCE CFO

2020-02-18 A 25,082 a 25,082 0.00 direct

MATES SHARON - Director - Officer CHAIRMAN, PRESIDENT & CEO

2020-02-18 A 83,542 a 83,542 0.00 direct

SATLIN ANDREW - Officer EVP AND CHIEF MEDICAL OFFICER

2020-02-18 A 33,417 a 33,417 0.00 direct

NEUMANN MARK - Officer EVP, CHIEF COMMERCIAL OFFICER

2020-02-18 A 26,754 a 26,754 0.00 direct

HALSTEAD MICHAEL - Officer EVP AND GENERAL COUNSEL

2020-02-18 A 33,417 a 33,417 0.00 direct

Elevate your investments